Tissue Biomarkers in Prognostication of Serous Ovarian Cancer following Neoadjuvant Chemotherapy

Table 2

Comparison of biomarkers score across the treatment groups.

Biomarker	Treatment group	Scoring of biomarker				P; (US-CT versus CT group)
		0	1	2	3
p53 (𝑛=100)	US-CT group (𝑛=50)	19	8	10	13	0.95
	NACT group (𝑛=50)	21	7	8	14
ER (𝑛=100)	US-CT group (𝑛=50)	29	7	8	6	0.238
	NACT group (𝑛=50)	26	7	15	2
PR (𝑛=100)	US-CT group (𝑛=50)	44	5	1	—	0.741
	NACT group (𝑛=50)	46	4	—	—
E-Cadherin (𝑛=100)	US-CT group (𝑛=50)	34	14	2	—	0.495
	NACT group (𝑛=50)	37	13	—	—
Bcl2 (𝑛=100)	US-CT group (𝑛=50)	46	4	—	—	0.304
	NACT group (𝑛=50)	42	6	2	—